I think Dr B is probably going to do the hiring as he has led clinical teams and knows what it takes to get trials to phase 3 without pauses with criteria selection and site location. In my mind BOM results should have hit the interim analysis about 3 months ago. He also has connections in the industry that Leo does not and maybe a few of those will come on board as clinical team leaders as there are 3 drugs with 2 drugs having multiple indications. I hope we have a deal for Prurisol within 3 months. It should not take as long as the Xenoport deal (6 months). As for B, probably waiting on SPA and interim analysis for B-ABSSI, interim analysis for BOM, and results of B-UP. These are catalysts and I don't think we should be sitting at current stock price. Hoping for a buyout of $8 to $35 per share within the next five years.